salicylic acid-(3,5-dibromo-2-hydroxy-benzylidenehydrazide) | 53429-74-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: salicylic acid-(3,5-dibromo-2-hydroxy-benzylidenehydrazide)
• 英文别名: 3,5-Dibrom-2-hydroxy-benzaldehyd-salicyloylhydrazon；Salicylsaeure-(3,5-dibrom-2-hydroxy-benzylidenhydrazid)；N'-[(E)-(3,5-dibromo-2-hydroxyphenyl)methylidene]-2-hydroxybenzohydrazide；N-[(E)-(3,5-dibromo-2-hydroxyphenyl)methylideneamino]-2-hydroxybenzamide
• CAS: 53429-74-6
• 化学式: C₁₄H₁₀Br₂N₂O₃
• 分子量: 414.053
• InChiKey: FWCLTYYMXFHMFZ-REZTVBANSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  81.9
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS
  申请人：Look Gary Charles

  公开号：US20110098309A1

  公开（公告）日：2011-04-28

  Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β1-42 oligomers from amyloid β1-42 monomers using acylhydrazide compounds. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β1-42 oligomers using acylhydrazide compounds.

  本发明涉及使用酰肼化合物抑制、调节和/或调节可溶性、球形、非纤维化、神经毒性淀粉样β1-42寡聚体从淀粉样β1-42单体形成的方法。本发明还涉及使用酰肼化合物治疗患有与可溶性、球形、非纤维化、神经毒性淀粉样β1-42寡聚体形成有关的疾病的患者的方法。
• METHODS OF ENHANCING COGNITIVE FUNCTION USING NON-PEPTIDIC COMPOUNDS
  申请人：Acumen Pharmaceuticals, Inc.

  公开号：EP2173340B1

  公开（公告）日：2013-07-10
• METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS
  申请人：Acumen Pharmaceuticals, Inc.

  公开号：EP2194975A2

  公开（公告）日：2010-06-16
• METHOD FOR TREATING A DISEASE ASSOCIATED WITH SOLUBLE, OLIGOMERIC SPECIES OF AMYLOID BETA 1-42
  申请人：Acumen Pharmaceuticals, Inc.

  公开号：EP2928561A1

  公开（公告）日：2015-10-14
• METHODS OF RESTORING COGNITIVE ABILITY USING NON-PEPTIDIC COMPOUNDS
  申请人：KRAFFT Grant A.

  公开号：US20090018084A1

  公开（公告）日：2009-01-15

  Disclosed are methods of enhancing cognitive impairment in a patient wherein the cognitive impairment is due to ADDL neurotoxicity. The methods employ non-peptidic compounds having a molecular weight of less than 1000 and which can antagonize against formation of neurotoxic ADDLs from Aβ 1-42 monomers.